Establishment of an Evaluation Method for Gene Silencing by Serial Pulmonary Administration of siRNA and pDNA Powders: Naked siRNA Inhalation Powder Suppresses Luciferase Gene Expression in the Lung

被引:20
作者
Ito, Takaaki [1 ]
Okuda, Tomoyuki [1 ]
Takayama, Ryo [1 ]
Okamoto, Hirokazu [1 ]
机构
[1] Meijo Univ, Fac Pharm, Dept Drug Delivery Res, Tempaku Ku, 150 Yagotoyama, Nagoya, Aichi 4688503, Japan
关键词
small interfering RNA (siRNA); plasmid DNA (pDNA); inhalable dry powder; spray-freeze-drying technique; pulmonary gene delivery; serial pulmonary administration; hyaluronic acid; polyethyleneimine; naked oligonucleotide therapy; naked gene therapy; FREEZE-DRIED POWDER; RNA INTERFERENCE; L-LEUCINE; DELIVERY; CELLS; MICE;
D O I
10.1016/j.xphs.2019.03.029
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In order to evaluate the in vivo effect of inhaled formulations, it is a gold standard to create a lung metastasis model by intravenously injecting cancer cells into an animal. Because the cancer grows from the blood vessel side, there is a possibility of underestimating the effect of an inhaled formulation administered to the lung epithelium side. In addition, the metastasis model has disadvantages in terms of preparation time and expense. The present study aimed to establish a new method to evaluate the effect of an inhaled small interfering RNA (siRNA) formulation that is more correct, more rapid, and less expensive. We investigated whether siRNA can suppress gene expression of plasmid DNA (pDNA) by serial pulmonary administration of siRNA and pDNA powders prepared by spray-freeze-drying. We revealed that formulations of dry siRNA powder significantly suppressed gene expression of pDNA powder compared with a control group with no siRNA. Naked siRNA inhalation powder with no vector showed the suppression of gene expression equivalent to that of an siRNA-polyethyleneimine complex without damaging tissues. These results show that the present method is suitable for evaluating the gene-silencing effect of inhaled siRNA powders. (C) 2019 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:2661 / 2667
页数:7
相关论文
共 21 条
[11]   Pulmonary drug delivery. Part I: Physiological factors affecting therapeutic effectiveness of aerosolized medications [J].
Labiris, NR ;
Dolovich, MB .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (06) :588-599
[12]  
Ledford H, 2018, NATURE, V560, P291, DOI 10.1038/d41586-018-05867-7
[13]   Gene expression - RNA interference in adult mice [J].
McCaffrey, AP ;
Meuse, L ;
Pham, TTT ;
Conklin, DS ;
Hannon, GJ ;
Kay, MA .
NATURE, 2002, 418 (6893) :38-39
[14]   Dual imaging of pulmonary delivery and gene expression of dry powder inhalant by fluorescence and bioluminescence [J].
Mizuno, Tomoyuki ;
Mohri, Kohta ;
Nasu, Shiho ;
Danjo, Kazumi ;
Okamoto, Hirokazu .
JOURNAL OF CONTROLLED RELEASE, 2009, 134 (02) :149-154
[15]   Optimized pulmonary gene transfection in mice by spray-freeze dried powder inhalation [J].
Mohri, Kohta ;
Okuda, Tomoyuki ;
Mori, Asami ;
Danjo, Kazumi ;
Okamoto, Hirokazu .
JOURNAL OF CONTROLLED RELEASE, 2010, 144 (02) :221-226
[16]   Development of spray-freeze-dried siRNA/PEI powder for inhalation with high aerosol performance and strong pulmonary gene silencing activity [J].
Okuda, Tomoyuki ;
Morishita, Masaki ;
Mizutani, Kimiyasu ;
Shibayama, Ayumi ;
Okazaki, Maki ;
Okamoto, Hirokazu .
JOURNAL OF CONTROLLED RELEASE, 2018, 279 :99-113
[17]   Gene Silencing in a Mouse Lung Metastasis Model by an Inhalable Dry Small Interfering RNA Powder Prepared Using the Supercritical Carbon Dioxide Technique [J].
Okuda, Tomoyuki ;
Kito, Daisuke ;
Oiwa, Ai ;
Fukushima, Michiko ;
Hira, Daiki ;
Okamoto, Hirokazu .
BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2013, 36 (07) :1183-1191
[18]   Inhalable Spray-Freeze-Dried Powder with L-Leucine that Delivers Particles Independent of Inspiratory Flow Pattern and Inhalation Device [J].
Otake, Hiroko ;
Okuda, Tomoyuki ;
Hira, Daiki ;
Kojima, Haruyoshi ;
Shimada, Yasuhiro ;
Okamoto, Hirozazu .
PHARMACEUTICAL RESEARCH, 2016, 33 (04) :922-931
[19]   FDA-Approved Oligonucleotide Therapies in 2017 [J].
Stein, Cy A. ;
Castanotto, Daniela .
MOLECULAR THERAPY, 2017, 25 (05) :1069-1075
[20]  
Suarez S, 2000, Respir Care, V45, P652